This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

63/100

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Biomarkers

Topic: Brain proteins, microglia and lab models

Background In MAPT (Multidomain Alzheimer Preventive Trial), a cognitive effect of multidomain intervention (MI) was showed in non-demented subjects with positive amyloid PET. However, screening eligible patients for multidomain intervention by PET is difficult to generalize in real-world settings. Methods MAPT study was a 3-year, randomized, placebo-controlled trial followed by a 2-year observational and optional extension. All participants were non-demented and randomly assigned (1:1:1:1) to the MI plus omega 3, MI plus placebo, omega 3 alone, or placebo alone group. The objectives were to assess the cognitive effect of MAPT interventions (omega 3 supplementation, MI, combined intervention) in non-demented subjects according to amyloid blood status at 12, 36, and 60 months. In this subgroup analysis (n = 483), amyloid status was defined by plasma Aβ42/40 ratio (cutoff ≤ 0.0107). The primary outcome measure was the change in cognitive composite score after a 1, 3, and 5-year clinical follow-up. Results The intention-to-treat (ITT) population included 483 subjects (161 positive and 322 negative amyloid participants based on plasma Aβ42/40 ratio). In the positive amyloid ITT population, we showed a positive effect of MI plus omega 3 on the change in composite cognitive score in 12 (raw p = .0350, 0.01917, 95% CI = [0.0136 to 0.3699]) and 36 months (raw p = .0357, 0.2818, 95% CI = [0.0190 to 0.5446]). After correction of multiple comparisons and adjustments, these differences were not significant (adjusted p = .1144 and .0690). In the per-protocol positive amyloid group (n = 154), we observed a significant difference between the combined intervention and placebo groups at 12 (p = .0313, 0.2424, 0.0571 to 0.4276) and 36 months (p = .0195, 0.3747, 0.1055 to 0.6439) persisting after adjustment. In the ITT and per-protocol analyses, no cognitive effect was observed in the positive and negative amyloid group at 60-month visit. Conclusions These findings suggest a benefit of MI plus omega 3 in positive blood amyloid subjects. This promising trend needs to be confirmed before using blood biomarkers for screening in preventive trials. Trial registration ClinicalTrials.gov Identifier: NCT01513252 .

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Delrieu, J., Vellas, B., Guyonnet, S., Cantet, C., Ovod, V., Li, Y., et al. (2023). Cognitive impact of multidomain intervention and omega 3 according to blood Aβ42/40 ratio: a subgroup analysis from the randomized MAPT trial. Alzheimer's research & therapy. https://doi.org/10.1186/s13195-023-01325-3

Vancouver

Delrieu J, Vellas B, Guyonnet S, Cantet C, Ovod V, Li Y, et al. Cognitive impact of multidomain intervention and omega 3 according to blood Aβ42/40 ratio: a subgroup analysis from the randomized MAPT trial. Alzheimer's research & therapy. 2023. doi:10.1186/s13195-023-01325-3. PMID: 37872582.

BibTeX

@article{delrieu2023-37872582,
  author  = {Delrieu, J. and Vellas, B. and Guyonnet, S. and Cantet, C. and Ovod, V. and Li, Y. and Bollinger, J. and Bateman, R. and others},
  title   = {{Cognitive impact of multidomain intervention and omega 3 according to blood Aβ42/40 ratio: a subgroup analysis from the randomized MAPT trial}},
  journal = {Alzheimer's research \& therapy},
  year    = {2023},
  doi     = {10.1186/s13195-023-01325-3},
  pmid    = {37872582},
  url     = {https://doi.org/10.1186/s13195-023-01325-3}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Results The intention-to-treat (ITT) population included 483 subjects (161 positive and 322 negative amyloid participants based on plasma Aβ42/40 ratio).
After correction of multiple comparisons and adjustments, these differences were not significant (adjusted p = .1144 and .0690).
In the per-protocol positive amyloid group (n = 154), we observed a significant difference between the combined intervention and placebo groups at 12 (p = .0313, 0.2424, 0.0571 to 0.4276) and 36 months (p = .0195, 0.3747, 0.1055 to 0.6439) persisting after adjustment.
Conclusions These findings suggest a benefit of MI plus omega 3 in positive blood amyloid subjects.

Why it matters

In this subgroup analysis of the MAPT trial, a multidomain intervention plus omega 3 was linked to better cognitive scores at some time points in people with positive plasma amyloid status, but these differences were not significant after correction for multiple comparisons. It does not establish a treatment, cure or prevention for Alzheimer's disease.

New to this subject? Start with our plain-English guide: Blood tests & biomarkers →

Study details

Participants483
Evidence strengthHigh

How this study scored 63/100

Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Alzheimer's research & therapy)
Journal's citation record	1 / 4	Alzheimer s Research & Therapy: journal h-index 146 (OpenAlex, 2026-10-29)
Study design	11 / 12	A randomized controlled trial (from PubMed type “Randomized Controlled Trial”)
Strength of evidence	5 / 5	Rated “high” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	3 / 5	2023 — within 6 year(s) of the newest study here
Sample size	2 / 4	483 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomized / blinded	2 / 2	Randomized and blinded or placebo-controlled (as stated in the record)
Times cited	2 / 7	Cited 13 times (OpenAlex, 2026-10-10)
Citations per year	1 / 5	2.6 citations a year over 5 year(s) since 2023
Impact for its field and year	3 / 6	Cited 3.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	1 / 6	Cited by 1 other studies in this library
Still being cited	1 / 4	Cited 13 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	2 / 4	Last-listed author Nicola Coley: h-index 39 (OpenAlex, whole career)
Institution's track record	2 / 3	Inserm: institution h-index 1,988 (OpenAlex)
Multicenter collaboration	3 / 3	OpenAlex lists 20 institution(s) in 3 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 37872582)
Free to read	2 / 2	Free to read
Total	63 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Biomarkers

Also tagged “placebo-controlled”

783 studies in the library carry the topic tag “placebo-controlled”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →